Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which insulin works best for Steroid-Induced high blood sugar? new study has answers

NCT ID NCT07599891

Disease control Sponsor: Max Healthcare Insititute Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two long-acting insulins, glargine and degludec, in 79 hospitalized adults whose blood sugar became high due to steroid medications. The goal was to see which insulin better controls blood sugar with fewer dangerous lows. Results help doctors choose the safest and most effective insulin for this common hospital problem.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

79 people

The number who actually took part.

Started

Sep 2023

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non pregnant adult patients * with or without Type 2 diabetes * above the age of 18 years * on glucocorticoid dose equivalent to \>20 mg and \<160 mg prednisolone daily for any indication * with glucocorticoid induced hyperglycemia (random blood glucose \>200 mg/dl) * who are requiring basal bolus insulin regimen

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucocorticoid induced hyperglycemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glucocorticoid induced hyperglycemia

Contacts and locations

Locations

  • Max Institute of Medical Education

    New Delhi, Saket, 110017, India